Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1188349 | 0.80 | HTT (0.51) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL11572650 | 0.77 | KDM4E (0.54) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2763230 | 0.76 | KDM4E (0.43) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14832080 | 0.75 | LRRK2 (0.50) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2764283 | 0.74 | KDM4E (0.43) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3723330 | 0.72 | SMN1; SMN2 (0.57) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3726803 | 0.71 | MALT1 (0.49) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16439065 | 0.70 | L3MBTL1 (0.46) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL612506 | 0.70 | KDM4E (1.00) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL24394890 | 0.69 | KDM4E (0.45) | KDM4EMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321777-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9115134-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | SANOFI (FR) | 2014-01-02 | — | — | US | disclosed |
| US-8546393-B2 | 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120165326-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
| EP-2393793-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| WO-2010089509-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
| EP-2178881-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | Sanofi-Aventis (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009056692-A2 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165326-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | MET, NR4A1, NR1I3 | KDM4E 2085/4885MEN1 4207/4885KMT2A 1398/4885 |
| US-20150344484-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | KDM4E 711/4885MEN1 1118/4885KMT2A 996/4885 |
| US-20140005189-A1 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | MET, TPMT, MERTK | KDM4E 711/4885MEN1 1118/4885KMT2A 996/4885 |
| US-20100298315-A1 | NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS | BMX, MET, TPMT | KDM4E 752/4885MEN1 2500/4885KMT2A 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.